Claim 1: a cell is selected from the group consisting of a Haematopoietic stem cell (HSC), and progenitor cell, a mesenchymal stem cell (MSC), where the route / B catenin Wnt Signalling in the cell is activated, for use in the treatment of a ENFE Rmedad of retinal degeneration.Claim 5: cell for use in the treatment of a disease of retinal degeneration in any of claims 1 to 4, in which the retinal degeneration disease selected from the group consisting of related Macular Degeneration, retinitis pigmentosa, With the age, Stargardt's disease, cone-rod Dystrophy,Congenital stationary night blindness, Leber congenital amaurosis, viteliforme Best macular Dystrophy, anterior ischemic Optic neuropathy, coroideremia, age-related Macular Degeneration, foveomacular Dystrophy, corneoretiniana Bietti Crystalline dystrophy syndrome Usher, a degenerative condition derived from a primary retinal Pathology.Claim 26: a Pharmaceutical composition selected from the group consisting of: 1) a Pharmaceutical composition comprising at least one cell is selected from the group consisting of a Haematopoietic stem cell (HSC), a progenitor cell, a mesenchymal stem cell (MSC ) and any combination thereof,In the route / B catenin WNT signaling is activated in these cells, and a pharmaceutically acceptable Carrier, and 2) a Pharmaceutical composition comprising at least one cell is selected from the group consisting of a Haematopoietic stem cell (HSC), a cell Progen Itora, mesenchymal stem cell (MSC) and any combination thereof,In combination with an Activator of The Pathway of WNT signaling / B - catenin or an inhibitor of a repressor of the route / B catenin WNT signaling and a pharmaceutically acceptable Carrier.Claim: a 27 Kit selected from the group consisting of: 1) a kit that includes at least one cell is selected from the group consisting of a Haematopoietic stem cell (HSC), a progenitor cell, a mesenchymal stem cell (MSC) and any combination of them in the The route / B catenin WNT
